Genocea Biosciences, Inc.
100 Acorn Park Drive
Cambridge, MA 02140
June 4, 2018
Via EDGAR Transmission
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: Genocea Biosciences, Inc.
Registration Statement on Form S-3 (File No. 333-225086)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Genocea Biosciences, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date of its Registration Statement on Form S-3 (File No. 333-225086) (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that it will be declared effective on June 5, 2018, or as soon as possible thereafter. The Company hereby authorizes Thomas Danielski of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Thomas Danielski of Ropes & Gray LLP at thomas.danielski@ropesgray.com or (617) 235-4961.
Very truly yours,
GENOCEA BIOSCIENCES, INC.
By: /s/ William D. Clark
William D. Clark
Chief Executive Officer
